Key facts
- This page summarizes Matthew Lang's Form 4 filing for Lyell Immunopharma, Inc. (LYEL).
- 3 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 26 Feb 2025, 19:36.
Matthew Lang - 10 Feb 2025 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)
- Reporting relationship
- Chief Business Officer
- Issuer ticker
- LYEL
- Reported as of
- 10 Feb 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 26 Feb 2025, 19:36:04 UTC
- Prior SEC filing
- 13 Feb 2024
- Next SEC filing
- 30 Apr 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Matthew Lang
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Matthew Lang filed Form 4 for Lyell Immunopharma, Inc. (LYEL) on 26 Feb 2025.
Change
- Previous filing in this sequence was filed on 13 Feb 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LYEL
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +112,500
- Change %
- +225%
- Price
- $0.000000
- Shares after
- 162,500
- Date
- 10 Feb 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LYEL
transaction
Derivative
Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +450,000
- Change %
- Price
- $0.000000
- Shares after
- 450,000
- Date
- 10 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 450,000
- Exercise price
- $0.5535
- Footnotes
- F2
LYEL
transaction
Derivative
Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +56,250
- Change %
- Price
- $0.000000
- Shares after
- 56,250
- Date
- 10 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 56,250
- Exercise price
- $0.5535
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
12.5% of the total number of restricted stock units will vest on August 9, 2025, and thereafter an additional 1/16th of the total number of restricted stock units will vest quarterly thereafter, subject to the reporting person providing service through the applicable vesting date.
Footnote F2
12.5% of the option shares will vest on August 9, 2025, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person providing service through the applicable vesting date.
Footnote F3
The reported transaction involved the reporting person's receipt of a grant of performance-based options, subject to vesting upon the achievement of specified performance criteria.